RGNX
Regenxbio Inc
NASDAQ: RGNX · HEALTHCARE · BIOTECHNOLOGY
$8.97
+6.79% today
Updated 2026-04-30
Market cap
$452.17M
P/E ratio
—
P/S ratio
2.65x
EPS (TTM)
$-3.76
Dividend yield
—
52W range
$7 – $16
Volume
0.8M
Regenxbio Inc (RGNX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-113.70%
Operating margin
-190.00%
ROE
-107.00%
ROA
-21.90%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2013 | $6.09M | $-5.39M | 94.68% | -78.46% | -88.50% |
| 2014 | $6.12M | $-4.00M | 83.55% | -60.16% | -65.41% |
| 2015 | $7.59M | $-22.81M | 80.19% | -304.92% | -300.62% |
| 2016 | $4.59M | $-62.97M | 79.10% | -1,423.84% | -1,372.13% |
| 2017 | $10.39M | $-73.17M | 83.56% | -730.15% | -704.02% |
| 2018 | $218.50M | $99.94M | 95.59% | 40.32% | 45.74% |
| 2019 | $35.23M | $-94.73M | 76.61% | -422.89% | -268.88% |
| 2020 | $154.57M | $-111.25M | 76.89% | -77.14% | -71.98% |
| 2021 | $470.35M | $127.84M | 88.98% | 34.01% | 27.18% |
| 2022 | $112.72M | $-280.32M | 51.61% | -233.20% | -248.68% |
| 2023 | $90.24M | $-263.49M | 58.76% | -297.12% | -291.99% |
| 2024 | $83.33M | $-227.10M | 59.72% | -280.03% | -272.54% |
| 2025 | $170.44M | $-193.88M | 88.09% | -94.58% | -113.75% |